Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 3 2Phase 1 2

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 10Lymphoma 8Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Neoplasms 3Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Hairy Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Burkitt Lymphoma 1Anemia 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × obinutuzumab × Clear all
NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

University of California, San Diego

Phase 1/2 Completed
32 enrolled 9 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Simcha IL-18, Inc.

Phase 1/2 Recruiting
316 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡